About Neuroene Therapeutics
Neuroene Therapeutics is a Healthcare company based in Charleston (United States) founded in 2015 by Sherine Chan. Novel Vitamin K-based therapeutics for epilepsy are developed. Neuroene Therapeutics offers products and services including Vitamin K Analogs and Mitochondrial HDAC1 Inhibitors. Its focus areas include Life Sciences, Neurology, Drugs and Epilepsy. Its competitors include Marinus Pharma, GenEp and Epygenix; 2 of its 3 listed competitors have raised funding.
Company details
Neuroene Therapeutics was founded in 2015 in Charleston, United States, originating from collaborative research by investigators at the Medical University of South Carolina. Focus is placed on developing therapeutics for neurological disorders, particularly novel Vitamin K-based treatments for epilepsy. Operations center on advancing these compounds through research and development in the biotechnology sector. Leadership includes co-founder Sherine Chan.
- Headquarters Charleston, United States
- Founders Sherine Chan
- SectorsHealthcare
- Website neuroenetherapeutics.com
- Latest Funding Round$598.01K (USD), Grant
May 2023
- Investors
Products & Services of Neuroene Therapeutics
Neuroene Therapeutics offers a comprehensive portfolio of products and services, including Vitamin K Analogs and Mitochondrial HDAC1 Inhibitors.
Orally bioavailable agents targeting mitochondrial health in diseases.
Inhibitors addressing neurological disorders via mitochondrial pathways.
Funding Insights of Neuroene Therapeutics
- Total Rounds 4
- Last Round Grant — $598,010
- First Round $224,803
(Jul 2016)
- Investors Count 1
All 4 funding rounds of Neuroene Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Neuroene Therapeutics
Neuroene Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Neuroene Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neuroene Therapeutics
1 people are tracked at Neuroene Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sherine Chan | Co-Founder | Leadership |
Complete people profiles for Neuroene Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neuroene Therapeutics
3 dated milestones of Neuroene Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Neuroene Therapeutics is founded.
- Funding First funding round of $225K.
- Funding Latest funding round, Grant, of $598K.
Competitors of Neuroene Therapeutics
Neuroene Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Marinus Pharma, GenEp and Epygenix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| marinuspharma.com | 2003 | Radnor, United States | $71.58M | 114 | Developer of therapeutics to treat seizure disorders | |
| genepbio.com | 2021 | Charlottesville, United States | $10.4M | Therapeutics for epilepsy are developed targeting ion channel mutations. | ||
| epygenix.com | 2016 | Paramus, United States | Develops drugs for rare neurological disorders including sleep, neurobehavioral, and epilepsy conditions. |
Detailed competitors of Neuroene Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Neuroene Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neuroene Therapeutics
Neuroene Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Neuroene Therapeutics is headquartered in Charleston, United States. It is registered at Charleston, South Carolina, United States.
Neuroene Therapeutics was founded in 2015 in Charleston, United States, originating from collaborative research by investigators at the Medical University of South Carolina. Focus is placed on developing therapeutics for neurological disorders, particularly novel Vitamin K-based treatments for epilepsy. Operations center on advancing these compounds through research and development in the biotechnology sector. Leadership includes co-founder Sherine Chan.
Neuroene Therapeutics's top competitors include Marinus Pharma, GenEp and Epygenix.
Neuroene Therapeutics offers Vitamin K Analogs and Mitochondrial HDAC1 Inhibitors.
Neuroene Therapeutics has 1 investor. Key investors include HHS.